

To,

Date: 01.07.2026

The Listing Department
National Stock Exchange of India Limited (NSE)
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Subject: Response to Observations on Outcome of Board Meeting – Financial Results Submitted on 17 June 2026

Dear Sir/Madam,

This is with reference to your email dated **25 June 2026** regarding the deficiencies observed in the Outcome of Board Meeting – Financial Results submitted by the Company on **17 June 2026**.

In this regard, we wish to submit the following for your kind consideration:

Certificate on Utilisation of Issue Proceeds:

The Company was listed on 29 May 2026. The financial results submitted relate to the financial year ended 31 March 2026 (i.e., for the period from 1 April 2025 to 31 March 2026), which pertains to the period prior to the Company's listing.

Accordingly, the Certificate on Utilisation of Issue Proceeds is not applicable to the aforesaid financial results and, therefore, has not been submitted.

We further confirm that the Certificate on Utilisation of Issue Proceeds shall be submitted along with the financial results for the half year ending 30 September 2026, as applicable under the relevant regulatory requirements.

Legible/Machine Readable Copy of Financial Results:

We are enclosing herewith a clear and legible copy of the Financial Results for your kind perusal and records.

We request you to kindly take the above clarification on record and consider the matter as complied with.

Thanking you,

For Q-LINE BIOTECH LIMITED

SAURABH GARG
Digitally signed by
SAURABH GARG
Date: 2026.07.01
17:08:27 +05'30'

Saurabh Garg
Managing Director
DIN: 02891621

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

Date: 17-06-2026

To,
The Listing Department
National Stock Exchange of India Limited,
"Exchange Plaza" 5th Floor, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400051

Company Code: QLINE

Subject: Outcome of Board Meeting and Disclosures for the year ended 31st March 2026.

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam, Pursuant to Regulations 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. June 17, 2026, has inter alia considered, and approved the following items of business:

1. Standalone & Consolidated Audited Financial Results for the Half Year and Financial Year ended March 31, 2026 together with the statement of Assets and Liabilities. Segment Report and Cash Flow Statements as on that date, along with the Auditor's Report thereon.

- Declaration confirming an unmodified opinion on the Standalone Financial Results pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- Declaration under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

2. Approved Internal Audit Report for the Year ended-31.03.2026.

The Board Meeting commenced at 3.30 P.M. and concluded at 6:45 p.m. of the same day. You are requested to take the above information on record.

Thanking You,

For Q Line Biotech Limited



Saurabh Garg
Managing Director
DIN- 02891621
Place: Lucknow

**SAURABH
H GARG**

Digitally signed
by SAURABH
GARG

Date: 2026.06.17
20:15:48 +05'30'

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

Q-LINE BIOTECH LIMITED
(Formerly Known as Q-Line Biotech Private Limited)
Address: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, India -226012

Website: www.qlinebiotech.com, Email: compliance@qlinebiotech.com, Phone Number: +91-5222435570

Standalone Profit & Loss Statement For The Half Year and Year Ended 31st March, 2026

Sr. No.	Particulars	Half Year Ended			Year Ended	
		31-03-2026	30-09-2025	31-03-2025	31-Mar-26	31-Mar-25
	Whether Results are Audited or Unaudited	Audited	Un-audited	Unaudited	Audited	Audited
I	Revenue From Operations	19755.66	14360.18	21,581.41	34115.84	31307.43
II	Other Income	307.41	265.94	852.32	573.36	882.96
III	Total Revenue (I+II)	20063.07	14626.12	22433.73	34689.19	32190.39
IV	Expenses:					
a	Cost Of Material Consumed	4801.76	3174.58	4,788.31	7976.35	5758.68
b	Purchase Of Stock-In-Trade	2,651.40	3,104.88	2,586.21	5,756.29	5,801.96
c	Changes In Inventories Of Finished Goods, Work-In-Progress And Stock -In-Trade	(135.95)	(180.91)	3,819.91	(316.86)	3,063.73
d	Employee Benefits Expenses	2,319.52	1,558.91	1,587.65	3,878.43	2,985.30
e	Finance Costs	1,072.03	815.67	830.08	1,887.70	1,491.32
f	Depreciation And Amortization Expense	669.45	408.38	320.96	1,077.83	692.93
g	Other Expenses	3,819.47	3,090.49	4,275.77	6,909.96	6,544.04
	Total Expenses	15197.69	11972.01	18208.90	27169.70	26337.96
V	Profit Before Exceptional And Extraordinary Items And Tax (III-IV)	4865.38	2654.11	4224.83	7519.49	5852.44
VI	Prior Period Items	-	-	263.90	-	572.57
VII	Profit Before Extraordinary Items And Tax (V-VI)	4865.38	2654.11	3960.93	7519.49	5279.87
VIII	Extraordinary Items-Income(Expenses)	(97.77)	-	1,374.51	(97.77)	1,374.51
IX	Profit Before Tax (VII-VIII)	4767.61	2654.11	5335.44	7421.73	6654.38
X	Tax Expense					
	Current Tax	1210.43	675.38	1,551.02	1885.81	1886.03
	Earliar Years Tax	0.31	(195.08)	61.70	(194.78)	61.70
	Deferred Tax	15.28	20.54	(51.84)	35.82	(33.02)
XI	Profit(Loss) For The Period From Continuing Operations (IX-X)	3541.60	2153.28	3774.55	5694.88	4739.66
XII	Profit (Loss) From Discontinuing Operations	-	-	-	-	-
XIII	Tax Expense Of Discontinuing Operations	-	-	-	-	-
XIV	Profit(Loss) From Continuing Operations After Tax (XI+XII-XIII)	3541.60	2153.28	3774.55	5694.88	4739.66
XV	Profit (Loss) For The Period	3541.60	2153.28	3774.55	5694.88	4739.66
XVI	Earning Per Equity Share (Face Value of Rs . 10/-) after considering extra ordinary items					
	Basic (In Rs.)	22.11	13.67	23.97	35.55	30.09
	Diluted (In Rs.)	22.11	13.67	23.97	35.55	30.09
XVII	Earning Per Equity Share (Face Value of Rs . 10/-) Before considering extra ordinary items					
	Basic (In Rs.)	23.10	13.67	15.24	36.16	21.37
	Diluted (In Rs.)	23.10	13.67	15.24	36.16	21.37

For And On Behalf Of Board,
Q-Line Biotech Limited
(Formerly Known as Q-Line Biotech Private Limited)


Saurabh Garg
Managing Director & Chairman
DIN: 02891621

Date:-17th June 2026
Place:- Lucknow

Q-LINE BIOTECH LIMITED
(Formerly Known as Q-Line Biotech Private Limited)

Address: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station

Lucknow, Uttar Pradesh, India -226012

Website: www.qlinebiotech.com, Email: compliance@qlinebiotech.com, Phone Number: +91-5222435570

CIN: U74120UP2010PLC042528

STANDALONE BALANCE SHEET AS AT 31ST MARCH 2026

(Amount in rupees lakhs, unless otherwise stated)

Particulars	As at 31 March 2026	As at 31 March 2025
A) EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share capital	1,627.50	157.50
(b) Reserves and surplus	23,111.57	18,834.19
	<u>24,739.07</u>	<u>18,991.69</u>
(2) Non Current Liabilities		
(a) Long term borrowings	8,611.93	8,241.18
(b) Deferred tax liabilities (Net)	-	-
(c) Other long term liabilities	199.20	136.75
(d) Long term provisions	435.46	261.47
	<u>9,246.60</u>	<u>8,639.39</u>
(3) Current Liabilities		
(a) Short term borrowings	12,684.24	7,585.01
(b) Trade payables		
(i) total outstanding dues of micro enterprises and small enterprises; and	267.05	214.32
(ii) total outstanding due of creditors other than micro enterprises and small enterprises	4,936.61	5,348.67
(c) Other current liabilities	2,221.76	2,491.71
(d) Short term provisions	610.34	1,599.67
	<u>20,719.99</u>	<u>17,239.38</u>
Total Equity and Liabilities (1+2+3)	<u>54,705.66</u>	<u>44,870.46</u>
B) ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment and intangible assets		
(i) Property, Plant & Equipment	11,853.06	5,347.24
(ii) Intangible Assets	2,272.97	1,989.32
(iii) Capital work-in-progress	1,539.68	5,903.11
(b) Non-current Investment	1,668.55	1,796.11
(c) Deferred tax asset (Net)	53.11	88.93
(d) Long-term loans and advances	92.29	158.42
(e) Other non-current assets	2,844.89	3,412.79
	<u>20,324.53</u>	<u>18,695.92</u>
(2) Current Assets		
(a) Inventories	9,475.86	9,021.34
(b) Trade receivables	12,691.25	8,277.64
(c) Cash and Bank Balances	7,592.67	4,445.98
(d) Short-term loans and advances	3,603.16	3,210.05
(e) Other current assets	1,018.18	1,219.53
	<u>34,381.12</u>	<u>26,174.54</u>
Total Assets (1+2)	<u>54,705.66</u>	<u>44,870.46</u>

For and on behalf of Board of Directors

Q-Line Biotech Limited

(Formerly Known as Q-Line Biotech Private Limited)



Saurabh Garg

Managing Director & Chairman

DIN: 02891621

Date: 17th June, 2026

Place: Lucknow

Q-LINE BIOTECH LIMITED
(Formerly Known as Q-Line Biotech Private Limited)

Address: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, India -226012

Website: www.qlinebiotech.com, Email: compliance@qlinebiotech.com, Phone Number: +91-5222435570

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH 2026

(Amount in rupees lakhs, unless otherwise stated)

Particulars	For the year ended on 31 March 2026 Audited	For the year ending 31 March 2025 Audited
Cash Flow from Operating Activities		
Net Profit before taxation	7,421.73	6,654.37
Adjustments for:		
Depreciation and amortization expense	1,077.83	692.93
Finance Cost	1,887.70	1,491.32
Bad Debts Written Off	16.84	317.15
Profit on Sale of Investment	-	(1,374.51)
(Profit)/loss on sale of Fixed Assets	(6.05)	2.62
Interest Income	(469.55)	(346.09)
Rent income	(7.03)	(8.14)
Provision for employee benefits (Gratuity) Net	184.90	292.54
Sundry Balance forfeited (income)	(41.91)	(1,853.97)
Sundry balance write off	5.71	54.57
Provision for Doubtful debts	31.42	16.78
Unrealised foreign exchange (gain)/loss	313.63	(23.63)
Operating Profit before Working Capital changes	10,415.23	5,915.94
Adjustments for:		
(Increase) /Decrease in Inventory	(454.52)	2,128.71
(Increase) /Decrease in Trade Receivables	(4,466.67)	(5,932.22)
(Increase) /Decrease in Short term loans and advances	(393.11)	232.03
(Increase) /Decrease in long term loan and advances	66.13	24.43
Addition in Fixed Deposits	255.79	(2,864.19)
(Increase) /Decrease in other current Assets	201.35	(16.45)
Increase/(Decrease) in Trade Payables	(629.14)	1,941.90
Increase/(Decrease) in Short Term Provision	(88.55)	156.36
Increase/(Decrease) in Other non-current liabilities	59.64	107.64
(Increase)/Decrease in Security Deposits	3.64	(377.82)
Increase/(Decrease) in OTHER CURRENT LIABILITY	(269.95)	1,703.92
Increase/(Decrease) in LONG TERM PROVISION	-	-
Cash Generated from Operations	4,699.82	3,020.26
Less: Tax Paid	(2,602.73)	(839.75)
Net Cash inflow / (outflow) from Operating activities (A)	2,097.10	2,180.51
Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment	(3,546.47)	(6,975.47)
Sale of property, plant & equipment	48.65	3.85
Proceed from sale of Investment	-	175.55
Investment in Subsidiary	-	(0.70)
Investment in Property	127.57	(1,067.27)
rent income	7.03	8.14
Advance Given to creditors for Property plant & equipment	-	(34.52)
Interest Income	469.55	346.09
Net Cash inflow / (outflow) from Investing activities (B)	(2,893.67)	(7,544.34)
Cash Flow from Financing Activities		
Repayment of Loans		
Proceeds from Issue in Share Capital	52.50	
Finance Cost	(1,887.70)	(1,491.32)
Proceeds from Short Term Borrowings	5,099.23	1,356.26
Proceeds from Long Term Borrowings	370.75	4,784.62
Net Cash inflow / (outflow) from Financing activities (C)	3,634.79	4,649.56
Net increase / (decrease) in cash and cash equivalents (A+B+C)	2,838.20	(714.27)
Cash and Cash Equivalents at the beginning of the year	1,234.82	1,949.08
Cash and Cash Equivalents at the end of the year	4,073.02	1,234.82
Note:1		
Components of Cash and cash equivalents		
- Cash on hand	54.67	42.67
- Balance with Banks	741.81	7.82
- Other Bank Balance (As per AS-3)	3,276.54	1,184.33
Total	4,073.02	1,234.82

Note:2 Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, financing and investing activities of the company are segregated.

For And On Behalf Of Board,

Q-Line Biotech Limited
(Formerly Known as Q-Line Biotech Private Limited)


Saurabh Garg


Date:-17th June 2026


Notes on Standalone Financial Result for the Half year and Year ended 31st March, 2026:-

- 1 The above result have been reviewed by the Audit Committee and have been approved by the Board of Directors of the company at their respective meetings held on 17th June, 2026.
- 2 The results for the year ended 31st March, 2026 has been audited by the statutory auditor of the company in compliance with regulation 33 of SEBI(listing obligations and disclosure requirements) regulation, 2015.
- 3 The figure for the half year ended March 31.2026, as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the Unaudited figures for the period April 1, 2025 to September 30, 2025. The figure for the half year ended March 31 2025, as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the Unaudited figures for the period April 1, 2024 to September 30, 2024. Unaudited Figures for the half year ended Sept 2024, and Sept 2025 has been extracted from the management certified financial for the half year ended 30th Sept, 2024 and 30th Sept 2025.
- 4 As per Accounting standard 17 on "segment Reporting" (AS-17), the company is having two segments i.e. Manufacturing and Trading into Biochemistry Reagents, Instruments and Consumables and accordingly segment disclosures has been given in result.
- 5 As per the Ministry of Corporate Affairs (MCA) notification dated 16th February, 2015, companies whose shares are listed on the SME Exchange as referred to in Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 are exempted from the compulsory requirement of adoption of Indian Accounting Standards (Ind AS). Accordingly, the Company continues to prepare its financial statements under Indian GAAP (AS framework), and these results have been presented in compliance with the aforesaid exemption.
- 6 Earnings per share have been computed in accordance with Accounting Standard (AS) 20 – Earnings Per Share, notified under the Companies (Accounting Standards) Rules, 2006. Basic EPS and Diluted EPS are calculated on the basis of the weighted average number of equity shares outstanding during the year. EPS is disclosed before extraordinary items and after extraordinary items, as required under AS 20, to present both the underlying performance and the total impact on shareholders. The weighted average number of shares is adjusted for any bonus issue, rights issue (including the bonus element therein), to ensure comparability across reporting periods.
- 7 The balance of Trade Payables, Trade Receivables, Loans and Advances, Deposits, Current Liabilities etc. are considered as per books of account, pending confirmations and reconciliation. In the Opinion of the management, since the amount due to/ from these parties are fully payable/recoverable, no material difference is expected to arise at the time of settlement, requiring accounting effect as on 31-03-2026.
- 8 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the same & taken the necessary impact of these changes and to the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect (if any) on the basis of such developments if needed.
- 9 Previous year/s/ period's figure have been regrouped/rearranged wherever necessary to make them comparable with the current year figures.

Date:-17th June 2026
Place:- Lucknow

For And On Behalf Of Board,
Q-Line Biotech Limited
(Formerly Known as Q-Line Biotech Private Limited)


Saurabh Garg
Managing Director & Chairman
DIN: 02891621




Q-LINE BIOTECH LIMITED
(Formerly Known as Q-Line Biotech Private Limited)
Address: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, India -226012

Website: www.qlinebiotech.com, Email: compliance@qlinebiotech.com, Phone Number: +91-5222435570

Segment wise Revenue, Results, Assets, and Liabilities for the Half Year and Year Ended 31/03/2026

(Amount In Lakhs)

Sr.No.	Particulars	Half Year Ended			Year Ended	
		31-03-2026	30-09-2025	31-03-2025	31-03-2026	31-03-2025
1	Segment-wise Revenue					
	Sale of Product Manufactured	14,068.88	8,953.77	12,325.78	23,022.65	16,897.01
	Sale of Traded Goods	5,686.78	5,406.41	9,255.63	11,093.19	14,410.42
	Total	19,755.66	14,360.18	21,581.41	34,115.84	31,307.43
	Less: Inter-segment revenue (if any)	-	-	-	-	-
	Net Sales or Income from Operation	19,755.66	14,360.18	21,581.41	34,115.84	31,307.43
2	Segment-wise Results					
	Profit/Loss before interest and Tax:					
	Sale of Product Manufactured	7,306.46	4,290.74	4,338.35	11,597.20	7,659.57
	Sale of Traded Goods	2,375.84	1,870.52	3,027.12	4,246.36	4,507.94
	Total	9,682.30	6,161.26	7,365.47	15,843.56	12,167.51
	Less: Finance Cost	1,072.03	815.67	830.08	1,887.70	1,491.32
	Less: Other Unallocable Expenses net of other Un-allocable Income	3,075.43	2,283.11	1,989.59	5,358.54	4,130.83
	Less: Depreciation	669.45	408.38	320.96	1,077.83	692.93
	Total Profit Before Tax	4,865.38	2,654.10	4,224.83	7,519.49	5,852.43
	Segment-wise Assets					
3	Sale of Product Manufactured	23,507.82	22,396.25	19,498.79	23,507.82	19,498.79
	Sale of Traded Goods	7,385.45	8,318.41	6,979.28	7,385.45	6,979.28
	Other Unallocable Assets	23,812.39	19,378.34	18,392.39	23,812.39	18,392.39
	Total	54,705.66	50,093.00	44,870.46	54,705.66	44,870.46
4	Segment-wise Liabilities					
	Sale of Product Manufactured	3,022.44	2,313.75	2,771.08	3,022.44	2,771.08
	Sale of Traded Goods	2,181.21	2,262.96	2,791.91	2,181.21	2,791.91
	Other Unallocable Liabilities	49,502.01	45,516.29	39,307.47	49,502.01	39,307.47
	Total	54,705.66	50,093.00	44,870.46	54,705.66	44,870.46



Q-LINE BIOTECH LIMITED

(Formerly Known as Q-Line Biotech Private Limited)

Address: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station

Lucknow, Uttar Pradesh, India -226012

Website: www.qlinebiotech.com, Email: compliance@qlinebiotech.com, Phone Number: +91-5222435570

Consolidated Profit & Loss Statement For The Half Year and Year Ended 31st March, 2026

Sr. No.	Particulars	Half Year Ended			Year Ended	
		31-03-2026	30-09-2025	31-03-2025	31-Mar-26	31-Mar-25
	Whether Results are Audited or Unaudited	Audited	Un-audited	Un-audited	Audited	Audited
I	Revenue From Operations	19793.76	14379.81	21,654.60	34173.57	31314.37
II	Other Income	303.03	267.30	852.32	570.34	882.96
III	Total Revenue (I+II)	20096.79	14647.11	22506.92	34743.90	32197.33
IV	<u>Expenses:</u>					
a	Cost Of Material Consumed	4872.20	3099.43	4,961.93	7971.63	5760.20
b	Purchase Of Stock-In-Trade	2600.27	3175.83	2,483.13	5776.10	5801.96
c	Changes In Inventories Of Finished Goods, Work-In-Progress And Stock -In-Trade	-138.14	-198.85	3,822.02	-337.00	3065.84
d	Employee Benefits Expenses	2406.47	1598.61	1,598.88	4005.08	3027.46
e	Finance Costs	1111.02	830.66	830.08	1941.68	1491.32
f	Depreciation And Amortization Expense	670.29	408.77	321.19	1079.06	703.37
g	Other Expenses	3845.11	3108.10	4,307.08	6953.21	6603.86
	Total Expenses	15367.22	12022.54	18324.31	27389.76	26454.01
V	Profit Before Exceptional And Extraordinary Items And Tax (III-IV)	4729.57	2624.58	4182.62	7354.15	5743.33
VI	Prior Period Expenses					
	Prior Period Expenses	0.00	0.00	265.22	0.00	572.57
VII	Profit Before Extraordinary Items And Tax (V-VI)	4,729.57	2,624.58	3,917.40	7,354.15	5,170.75
VIII	Extraordinary Items	(99.17)	-	(1,696.97)	(99.17)	(1,696.97)
IX	Profit Before Tax (VII-VIII)	4630.40	2624.58	2220.44	7254.97	3473.79
X	<u>Tax Expense</u>					
	Current Tax	1,210.43	675.38	1,551.02	1,885.81	1,886.03
	Earliar Years Tax	0.31	(195.08)	61.70	(194.78)	61.70
	Deferred Tax	(20.88)	12.65	(42.48)	(8.23)	(42.18)
XI	Profit(Loss) For The Period From Continuing Operations (IX-X)	3,440.55	2,131.62	650.19	5,572.17	1,568.23
XII	Share of Profit (loss) of- Associates	-	-	233.71	-	352.88
XIII	Profit(Loss) From Continuing Operations After Tax (XI+XII)	3440.55	2131.62	883.90	5572.17	1921.11
XIV	Share of Profit/(Loss) attributable to Minority Interest	0.00	0.00	0.00	0.00	0.00
XV	Profit attributable to Parent Equity Shareholders (XIII-XIV)	3440.55	2131.62	883.90	5572.17	1921.11
XVI	Earning Per Equity Share (Face Value of Rs . 10/-) after considering extra ordinary items					
	Basic (In Rs.)	21.48	13.53	5.61	34.79	12.20
	Diluted (In Rs.)	21.48	13.53	5.61	34.79	12.20
XVII	Earning Per Equity Share (Face Value of Rs . 10/-) Before considering extra ordinary items					
	Basic (In Rs.)	22.10	13.53	16.39	35.41	22.97
	Diluted (In Rs.)	22.10	13.53	16.39	35.41	22.97

For And On Behalf Of Board,
Q-Line Biotech Limited
(Formerly Known as Q-Line Biotech Private Limited)

Saurabh Garg
Managing Director & Chairman
DIN: 02891621

Date:-17th June 2026

Place:- Lucknow

Q-LINE BIOTECH LIMITED
(Formerly Known as Q-Line Biotech Private Limited)
Address: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, India -226012
Website: www.qlinebiotech.com, Email: compliance@qlinebiotech.com, Phone Number: +91-5222435570

CONSOLIDATED BALANCE SHEET AS AT 31st MARCH, 2026

(Rs In Lakhs)

Sr. No.	Particulars	AS AT 31-03-2026	AS AT 31-03-2025
I	Equity And Liabilities	Audited	Audited
1	Shareholders Funds		
a	Share Capital	1,627.50	157.50
b	Reserves And Surplus	22,991.70	18,837.92
	Total (1)	24,619.20	18,995.42
2	Share Application Money Pending Allotment		
	Total (2)	-	-
3	Non-Current Liabilities		
a	Long Term Borrowings	9,619.23	8,241.18
b	Deferred Tax Liabilities (Net)	-	-
c	Other long term liabilities	199.20	136.75
d	Long term provisions	439.27	261.82
	Total (3)	10,257.70	8,639.74
4	Current Liabilities		
a	Short term borrowings	12,929.04	8,253.80
b	Trade Payables		
	(i) total outstanding dues of micro enterprises and small enterprises; and	267.28	214.32
	(ii) total outstanding due of creditors other than micro enterprises and small	4,937.05	5,348.17
c	Other Current Liabilities	2,247.90	2,498.36
d	Short Term Provisions	610.40	1,599.68
	Total (4)	20,991.67	17,914.33
	Total Equity & Liabilities (1+2+3+4)	55,868.57	45,549.49
II	Assets		
1	Non-Current Assets		
a	Property Plant & Equipment & Intangible Assets		
	(i) Property, Plant & Equipment	11,858.04	5,347.24
	(ii) Intangible Assets	2,272.97	1,989.32
	(iii) Goodwill on Consolidation	26.86	27.76
	(iv) Capital work-in-progress	1,539.68	5,903.11
	(v) Intangible Assets under development	391.00	352.30
b	Non-current Investment	1,667.35	1,794.91
c	Deferred tax asset (Net)	106.32	98.09
d	Long-Term Loans And Advances	547.15	158.42
e	Other Non-Current Assets	3,053.49	3,414.52
	Total (1)	21,462.86	19,085.67
2	Current Assets		
a	Inventories	9,495.99	9,021.34
b	Trade Receivables	12,582.37	8,260.25
c	Cash and Bank Balances	7,643.65	4,702.60
d	Short-Term Loans And Advances	3,657.42	3,258.04
e	Other Current Assets	1,026.28	1,221.59
	Total (2)	34,405.71	26,463.82
	Total Assets (1+2)	55,868.57	45,549.49

For And On Behalf Of Board,
Q-Line Biotech Limited
(Formerly Known as Q-Line Biotech Private Limited)

Date:-17th June 2026
Place:-Lucknow


Saurabh Garg
Managing Director & Chairman
DIN: 02891621

CONSOLIDATED STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

Particulars	(Amount in ₹ Lakhs)	
	For the year ended March 31, 2026	For the year ended March 31, 2025
	Audited	Audited
Cash Flow from Operating Activities		
Net Profit before taxation	7,254.97	3,473.79
Adjustments for:		
Depreciation and amortization expense	1,079.06	703.37
Finance Cost	1,941.68	1,491.32
Bad Debts/Written Off	16.84	317.15
Loss on Sale of Investment	-	1,696.97
(Profit)/loss on sale of Fixed Assets	(6.05)	2.62
Interest Income	(466.50)	(346.09)
rent income	(7.03)	(8.14)
Provision for employee benefits(Gratuity)	188.42	292.90
Sundry Balance forfeited(income)	(41.91)	1,217.51
Sundry balance write off	5.71	54.57
Provision for Doubtful debts	31.42	16.78
Unrealised foreign exchange (gain)/loss	313.63	(23.63)
Operating Profit before Working Capital changes	10,310.23	8,889.10
Adjustments for:		
(Increase) /Decrease in Inventory	(474.65)	2,130.82
(Increase) /Decrease in Trade Receivables	(4,375.18)	(5,914.83)
(Increase) /Decrease in Short term loans and advances	(399.38)	78.22
(Increase) /Decrease in long term loan and advances	(388.73)	24.43
Withdrawal in Fixed Deposits	276.39	(3,091.69)
(Increase) /Decrease in other current Assets	195.30	(18.50)
Increase/(Decrease) in Trade Payables	(627.97)	(1,134.26)
Increase/(Decrease) in Short Term Provision	(88.55)	156.36
Increase/(Decrease) in Other non-current liabilities	62.45	107.64
(Increase)/Decrease in Security Deposits	3.64	(375.14)
Statutory Dues Paid (Adjusted with R&S)	-	-
Increase/(Decrease) in Other Current Liabilities	(253.28)	1,708.57
Cash Generated from Operations	4,240.27	2,560.73
Less: Tax Paid	(2,602.73)	(839.75)
Net Cash inflow /(outflow) from Operating activities (A)	1,637.55	1,720.98
Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment	(3,591.37)	(6,975.47)
Sale of property, plant & equipment	48.66	3.85
Proceed from sale of Investment	-	(28.20)
Investment in Subsidiary	-	0
Investment in Joint Venture	-	-
Investment in Property	127.57	(1,067.27)
rent income	7.03	8.14
Advance Given to creditors for Property plant & equipment	-	(34.52)
Interest Income	466.50	346.09
Net Cash inflow /(outflow) from Investing activities (B)	(2,941.61)	(7,747.38)
Cash Flow from Financing Activities		
Repayment of Loans	-	-
Changes in Share Capital	52.50	-
Finance Cost	(1,941.68)	(1,491.32)
Repayment of Borrowings	-	-
Proceeds from borrowings-Net	6,053.31	6,809.67
Dividend Paid	-	-
Net Cash inflow /(outflow) from Financing activities (C)	4,164.12	5,318.34
Net increase /(decrease) in cash and cash equivalents (A+B+C)	2,860.06	(708.07)
Cash and Cash Equivalents at the beginning of the year	1,263.94	1,972.02
Cash and Cash Equivalents at the end of the year	4,124.00	1,263.94
Note:1		
Components of Cash and cash equivalents		
- Cash on hand	55.03	43.03
- Balance with Banks	792.43	36.59
- Other Bank Balance (As per AS-3)	3,276.54	1,184.33
Total	4,124.00	1,263.94

Note:2 Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, financing and investing activities of the company are segregated.

For And On Behalf Of Board,
Q-Line Biotech Limited
(Formerly Known as Q-Line Biotech Private Limited)

Saurabh Garg
Managing Director & Chairman
DIN: 02891621

Date:-17th June 2026
Place:- Lucknow

Notes on Consolidated Financial Result for the Half year and Year ended 31st March, 2026:-

- 1 The above result have been reviewed by the Audit Committee and have been approved by the Board of Directors of the company at their respective meetings held on 17th June, 2026.
- 2 The results for the year ended 31st March, 2026 has been audited by the statutory auditor of the company in compliance with regulation 33 of SEBI(listing obligations and disclosure requirements) regulation, 2015.
- 3 The figure for the half year ended March 31 2026, as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the Unaudited figures for the period April 1, 2025 to September 30, 2025. The figure for the half year ended March 31 2025, as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the Unaudited figures for the period April 1, 2024 to September 30, 2024. Unaudited Figures for the half year ended Sept 2024, and Sept 2025 has been extracted from the management certified financial for the half year ended 30th Sept, 2024 and 30th Sept 2025.
- 4 As per Accounting standard 17 on "segment Reporting" (AS-17), the company is having two segments i.e. Manufacturing and Trading into Biochemistry Reagents, Instruments and Consumables and accordingly segment disclosures has been given in result.
- 5 As per the Ministry of Corporate Affairs (MCA) notification dated 16th February, 2015, companies whose shares are listed on the SME Exchange as referred to in Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 are exempted from the compulsory requirement of adoption of Indian Accounting Standards (Ind AS). Accordingly, the Company continues to prepare its financial statements under Indian GAAP (AS framework), and these results have been presented in compliance with the aforesaid exemption.
- 6 Earnings per share have been computed in accordance with Accounting Standard (AS) 20 – Earnings Per Share, notified under the Companies (Accounting Standards) Rules, 2006. Basic EPS and Diluted EPS are calculated on the basis of the weighted average number of equity shares outstanding during the year. EPS is disclosed before extraordinary items and after extraordinary items, as required under AS 20, to present both the underlying performance and the total impact on shareholders. The weighted average number of shares is adjusted for any bonus issue, rights issue (including the bonus element therein), to ensure comparability across reporting periods.
- 7 The balance of Trade Payables, Trade Receivables, Loans and Advances, Deposits, Current Liabilities etc. are considered as per books of account, pending confirmations and reconciliation. In the Opinion of the management, since the amount due to/ from these parties are fully payable/recoverable, no material difference is expected to arise at the time of settlement, requiring accounting effect as on 31-03-2026.
- 8 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the same & taken the necessary impact of these changes and to the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect (if any) on the basis of such developments if needed.
- 9 Previous year's/ period's figure have been regrouped/rearranged wherever necessary to make them comparable with the current year figures.

Date:-17th June 2026
Place:- Lucknow

For And On Behalf Of Board,
Q-Line Biotech Limited
(Formerly Known as Q-Line Biotech Private Limited)


Saurabh Garg
Managing Director & Chairman
DIN: 02891621

Q-LINE BIOTECH LIMITED (Formerly Known as Q-Line Biotech Private Limited) Address: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station Lucknow, Uttar Pradesh, India -226012 Website: www.qlinebiotech.com, Email: compliance@qlinebiotech.com, Phone Number: +91-5222435570						
Consolidated Segment wise Revenue, Results, Assets, and Liabilities for the Half Year and Year Ended 31/03/2026						
(Amount In Lakhs)						
Sr.No.	Particulars	Half Year Ended			Year Ended	
		31-03-2026	30-09-2025	31-03-2025	31-03-2026	31-03-2025
1	Segment-wise Revenue					
	Sale of Product Manufactured	14,068.88	8,953.77	12,356.92	23,022.65	16,897.01
	Sale of Traded Goods	5,724.88	5,426.04	9,297.68	11,150.92	14,417.36
	Total	19,793.76	14,379.81	21,654.60	34,173.57	31,314.37
	Less: Inter-segment revenue (if any)	-	-	-	-	-
	Net Sales or Income from Operation	19,793.76	14,379.81	21,654.60	34,173.57	31,314.37
2	Segment-wise Results					
	Profit/Loss before interest and Tax:					
	Sale of Product Manufactured	7,154.54	4,385.60	4,183.81	11,540.14	7,509.37
	Sale of Traded Goods	2,584.95	1,833.07	2,766.61	4,418.02	4,388.84
	Total	9,739.49	6,218.67	6,950.42	15,958.16	11,898.22
	Less: Finance Cost	1,111.02	830.66	830.08	1,941.68	1,491.32
	Less: Other Unallocable Expenses net of other Un-allocable Income	3,327.78	2,354.68	3,578.21	5,682.46	6,229.75
	Depreciation	670.29	408.77	321.19	1,079.06	703.37
	Total Profit Before Tax	4,630.40	2,624.57	2,220.94	7,254.97	3,473.78
3	Segment-wise Assets					
	Sale of Product Manufactured	23,420.00	22,204.25	19,488.42	23,420.00	19,488.42
	Sale of Traded Goods	7,384.53	8,380.70	6,972.27	7,384.53	6,972.27
	Other Unallocable Assets	25,064.05	20,634.62	19,088.80	25,064.05	19,088.80
	Total	55,868.58	51,219.57	45,549.49	55,868.58	45,549.49
4	Segment-wise Liabilities					
	Sale of Product Manufactured	3,017.74	2,261.12	2,771.20	3,017.74	2,771.20
	Sale of Traded Goods	2,186.60	2,316.85	2,791.30	2,186.60	2,791.30
	Other Unallocable Liabilities	50,664.24	46,641.60	39,986.99	50,664.24	39,986.99
	Total	55,868.58	51,219.57	45,549.49	55,868.58	45,549.49



INDEPENDENT AUDITOR'S REPORT ON THE HALF YEARLY AND YEAR TO DATE AUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY

TO
THE BOARD OF DIRECTORS,
Q-LINE BIOTECH LIMITED

Opinion

We have audited the accompanying statement of half yearly and year to date standalone financial results of Q-LINE BIOTECH LIMITED ("the company") for the half year and year ended March 31, 2026 ("Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- is presented in accordance with the requirements of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Management and Board of Directors are responsible for the preparation of these standalone annual financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material



misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3) (i) of the Companies Act 2013, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

- a) The standalone annual financial results include the results for the half year ended March 31, 2026, being the balancing figure between audited figures in respect of the full financial year and the unaudited year to date figure up to the six months ended September 30, 2025 as certified by management.
- b) The standalone annual financial results include the results for the half year ended March 31, 2025, being the balancing figure between audited figures in respect of the full financial year and the unaudited year to date figure up to the six months ended September 30, 2024 as certified by management.

Our opinion on the standalone annual financial results is not modified in respect of these matters.

For R K Jagetiya & Co
Chartered Accountants
FRN 146264W


(Ravi K. Jagetiya)
Proprietor
Membership No. 134691
Date: 17th June, 2026
Place: Mumbai
UDIN: 26134691EUQTNA8625



INDEPENDENT AUDITOR'S REPORT ON THE HALF YEARLY AND YEAR TO DATE AUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY

TO
THE BOARD OF DIRECTORS,
Q-LINE BIOTECH LIMITED

Opinion

We have audited the accompanying statement of half yearly and year to date consolidated financial results of Q-LINE BIOTECH LIMITED ("the Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the half year and year ended March 31, 2026 ("Statement") attached herewith, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a) Includes the annual financial results of the following entity:
 - I. Q-Line Innovations Private Limited, and
 - II. Q-Line Iris Private Limited
- b) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- c) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements. The Group's Management and Board of Directors are responsible for the preparation of these consolidated annual financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the consolidated annual financial results, the Management and Board of Directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3) (i) of the Companies Act 2013, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Group has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters


- a) The Consolidated annual financial results include the results for the half year ended March 31, 2026, being the balancing figure between audited figures in respect of the full financial year and the unaudited year to date figure up to the six months ended September 30, 2025 as certified by management.
- b) The Consolidated annual financial results include the results for the half year ended March 31, 2025, being the balancing figure between audited figures in respect of the full financial year and the unaudited year to date figure up to the six months ended September 30, 2024 as certified by management.

Our opinion on the Consolidated annual financial results is not modified in respect of these matters.

For R K Jagetiya & Co

Chartered Accountants

FRN 146264W



(Ravi K Jagetiya)

Proprietor

Membership No. 134691

Date: 17th June, 2026

Place: Mumbai

UDIN: 26134691SFKHQU2831



MANAGING DIRECTOR AND CHIEF FINANCIAL OFFICER (CFO) CERTIFICATE
[Pursuant to proviso to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015]

To,

The Board of Directors,
Q-LINE BIOTECH LIMITED,

CIN: U74120UP2010PLC042528

Registered Office Address:

298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station,
Lucknow, Uttar Pradesh, India, 226012.

Corporate Office Address:

298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station,
Lucknow, Uttar Pradesh, India, 226012.

**Subject: Certificate from MD & CFO under Regulation 33(2)(a) of SEBI
(Listing Obligations and Disclosures Requirements) Regulations, 2015,
(as amended).**

Respected Members of the Board,

We, Saurabh Garg, Managing Director and Meenal Gupta, Chief Financial Officer of Q-Line Biotech Limited ("the Company"), to the best of our knowledge and belief, certify that the financial results for the second half year and financial year ended on March 31, 2026, as submitted before the Board of Directors of Q-Line Biotech Limited ("the Company"):-

"Do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading".

This certificate is issued after a thorough examination of the Company's records and compliance status, ensuring that all legal obligations related to the financial results for the specified period have been duly met.



Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

This certificate is given by the undersigned to the best of their knowledge and belief, with full awareness that full reliance is placed by the management of the company on its accuracy and integrity.

This certificate is issued for the purpose of compliance of Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, (as amended).


Thanking you,
Yours faithfully,

For Q-Line Biotech Limited,



Saurabh Garg
Managing Director
DIN: 02891621

For Q-Line Biotech Limited,



Meenal Gupta
Chief Financial Officer
PAN: ABHPG6642E

Corp. Address: 298-281, Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro
Station, Lucknow, Uttar Pradesh, India, 226012

Corp. Address: 298-281, Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro
Station, Lucknow, Uttar Pradesh, India, 226012

Place: Lucknow
Date: June 17, 2026

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

DECLARATION PURSUANT TO REGULATION 33(3) (d) OF SEBI (LISTING OBLIGATIONS & DISCLOSURE REQUIREMENTS), 2015 REGARDING AUDIT REPORT WITH UNMODIFIED OPINION.

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, M/s. R.K Jagetiya & Co., Mumbai Chartered Accountants (Firm Registration No. 146264W) have issued Audit Reports with unmodified opinions on the Standalone & Consolidated Audited Financial Results of the Company for the year ended on March 31, 2026, which were approved by the Board of Directors at its meeting held today, i.e. June 17, 2026.

Thanking you,
Yours faithfully,

For Q-Line Biotech Limited,



Saurabh Garg
Managing Director
DIN: 02891621

Corp. Address: 298-281, Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro
Station, Lucknow, Uttar Pradesh, India,
226012

Place: Lucknow
Date: June 17, 2026

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528